Denali Therapeutics is a technology company.
Denali Therapeutics has raised $350.0M across 2 funding rounds.
Denali Therapeutics has raised $350.0M in total across 2 funding rounds.
Denali Therapeutics has raised $350.0M in total across 2 funding rounds.
Denali Therapeutics's investors include ARCH Venture Partners, Borealis Ventures, Flagship Ventures, F-Prime Capital Partners, InterWest, Samsara BioCapital, Vivo Capital, Wildcat Ventures.
Denali Therapeutics is a biopharmaceutical company developing therapies for neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, as well as lysosomal storage diseases.[1][2][3] It serves patients with these conditions by creating disease-modifying treatments that address unmet needs through innovative drug delivery across the blood-brain barrier (BBB), powered by its proprietary Transport Vehicle (TV) technology.[1][3][4] The company solves core challenges in neurodegeneration, such as ineffective brain penetration of therapeutics, with a pipeline in clinical and preclinical stages; it reported $422.8 million in revenue for 2024 and anticipates a commercial launch of tividenofusp alfa in late 2025 or early 2026, signaling strong growth momentum.[1]
Founded in 2015 by Flagship Pioneering, Denali Therapeutics emerged from advancing science in neurodegenerative diseases, which were seen as ripe for breakthroughs in understanding causes and developing therapies.[4] CEO and co-founder Ryan Watts, driven by personal loss—his mother to Alzheimer's—leads with purpose, blending scientific expertise in genetic pathways and drug development.[7] Early traction included partnerships like Biogen and clinical milestones, such as dosing first patients in Phase 1b studies for Parkinson's (DNL151, DNL201), ALS (DNL747), and Alzheimer's by 2019, alongside collaborations like SIRION Biotech for CNS gene therapies.[4]
Denali rides the wave of rapid advances in neurodegeneration science, enabling targeted therapies amid rising prevalence of diseases like Alzheimer's and Parkinson's due to aging populations.[4][7] Timing aligns with breakthroughs in genetic insights and biotherapeutics, where market forces favor BBB-crossing innovations amid limited existing options.[1][3] By pioneering TV technology and partnerships (e.g., Biogen, Sanofi), Denali influences the ecosystem, accelerating CNS drug development and shifting focus from symptom management to prevention and cures.[1][4][7]
Denali is poised for pivotal growth with tividenofusp alfa's potential 2025-2026 launch and ongoing pipeline advances toward preventative therapies via genotyping, scans, and toxic protein clearance—possibly within 10-15 years.[1][7] Trends like AI-driven drug discovery and expanded CNS gene therapies will shape its path, amplifying influence as it defeats degeneration through BBB innovation.[3][9] This positions Denali to transform lives, fulfilling its mission from a biotech pioneer to neurodegeneration leader.[2]
Denali Therapeutics has raised $350.0M across 2 funding rounds. Most recently, it raised $130.0M Series B in August 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2016 | $130.0M Series B | ARCH Venture Partners, Borealis Ventures, Flagship Ventures, F-Prime Capital Partners, InterWest, Samsara BioCapital, Vivo Capital, Wildcat Ventures | |
| May 1, 2015 | $220.0M Series A | ARCH Venture Partners, Borealis Ventures, Flagship Ventures, F-Prime Capital Partners, InterWest, Samsara BioCapital, Vivo Capital, Wildcat Ventures |